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Anxiety and depression add to the burden of Chronic Fatigue Syndrome (CFS), 
Fibromyalgia (FM), and Type 1 Diabetes Mellitus (T1DM). Metacognitions play a role in 
this distress. The Metacognitions about Symptom Control Scale (MaSCS) measures 
metacognitive beliefs regarding symptoms but has weaknesses. The current study created a 
revised MaSCS (MaSCS-R) in English, German, and Arabic versions using CFS, FM, and 
T1DM samples, and examined the transcultural, transdiagnostic, and concurrent validity of 
metacognitions about symptom control. This study used data from a total of 563 participants 
clinically diagnosed with CFS (n = 124; English), FM (n = 348; German), or T1DM (n = 91; 
Lebanese). CFS and FM data had been used in earlier published studies but were subjected to 
new analyses. CFS data was used to create the English version of the MaSCS-R, and FM and 
T1DM data for German and Arabic versions. Metacognitions about worry, anxiety, 
depression, and symptom severity were measured. The three MaSCS-R versions, consisting 
of two factors (each with four items), had adequate psychometric properties, possessing 
configural and metric invariance. Metacognitive factors were associated with distress and 
symptom severity in all three samples. Metacognitions about symptom control have 
transcultural, transdiagnostic, and concurrent validity. 
Keywords: Long-term Health Conditions; Distress; Metacognitions; Transcultural.




1.1 Anxiety and depression in long-term health conditions 
 The burden of long-term health conditions (LTHCs) is increased by anxiety and 
depression symptoms, affecting individuals and increasing treatment costs for health care 
systems (Naylor et al., 2012). LTHCs are a global problem (World Health Organization, 
2017), requiring the development of effective treatments to reduce the, often co-occurring, 
distress (i.e. an amalgamation of anxiety and depression symptoms). Identifying targets for 
psychological intervention is an important step in treatment development. Given the global 
nature of this problem, identifying transculturally valid targets has even greater utility. The 
current study focusses on three different LTHCs: Chronic Fatigue Syndrome (CFS), 
Fibromyalgia (FM), and Type 1 Diabetes Mellitus (T1DM), with samples drawn from three 
countries (UK, Germany, and Lebanon). 
CFS is a debilitating condition characterized by profound, disabling fatigue, 
accompanied by numerous rheumatologic, flu-like, and neuropsychiatric symptoms. Anxiety 
and depression often add to the disease burden (Afari & Buchwald, 2003). FM refers to a 
type of chronic non-inflammable soft-tissue rheumatism, characterised by chronic 
widespread pain, sleep disturbances, and fatigue. The prevalence of emotional distress is high 
in FM (Thieme, Turk, & Flor, 2004). Diabetes mellitus results from an autoimmune response 
that destroys insulin-producing cells. There are several types of diabetes mellitus, with types 
1 and 2 being most common. People living with T1DM have elevated levels of anxiety and 
depression (Barnard, Skinner, & Peveler, 2006; Shaban, Fosbury, Kerr, & Cavan, 2006). 
1.2 Transcultural limitations of Western models of psychotherapy 
 Applying ‘Western-developed’ psychotherapy in other cultures is argued to be 
problematic (see Koç & Kafa, 2019 for a discussion), lacking transcultural validity. For 
example, Rathod, Kingdon, Smith, and Turkington (2005) found that, in an RCT using CBT 
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to improve insight in schizophrenia, African-Caribbeans had significantly poorer outcomes 
and significantly more drop-outs than Caucasians participants. Also, Lester, Artz, Resick, and 
Young-Xu (2010) looked at the impact of ethnicity on CBT for PTSD and found that twice as 
many African-Americans dropped out of treatment than Caucasians (although they found no 
differences in treatment outcomes between these ethnicities). Some authors have suggested 
that adapting psychotherapeutic approaches can address this issue. For example, Wampold 
(2015) presented a ‘contextual model’, consisting of three ‘pathways’, and proposed that, 
because it utilises common factors shared by psychotherapies, it maximises their transcultural 
validity. However, attempting to restructure (what the therapist has formulated to be) 
maladaptive cognitions may be inappropriate in certain cultural contexts. Culture plays a 
significant role in shaping cognitions (Dowd, 2003). The extent to which cognitions are 
adaptive or maladaptive is likely to vary as a function of cultural context. For example, 
cognitions relating to the maintenance of family structures, compared to those concerning an 
individual’s well-being, might be more adaptive for people from collectivistic than 
individualistic cultures (Hays & Iwamasa, 2006). Therefore, identifying suitable targets for 
cognitive restructuring needs to be repeatedly re-calibrated when working with people from 
different cultures. Alternatively, identifying transcultural targets might bypass this 
requirement, as well as having (potentially) many other benefits. For example, it is arguable 
that a good fitting, transculturally valid psychological model would describe more 
fundamental mechanisms underlying psychological distress. More accurate and efficient 
interventions could be derived from such models. Also, psychotherapists trained in one 
country could use their knowledge and skills to help patients in another, and equitable 
treatment effects might be achieved across cultures, because interventions could be derived 
from transcultural psychological models. 
1.3 Metacognitive Therapy 
RUNNING HEAD: Are metacognitions in long-term health conditions transcultural? 
 
6 
Over the last 20 years has seen the development of Metacognitive Therapy (MCT; 
Wells, 2009), which offers a novel way of conceptualising and treating psychological 
distress. Metacognitions are a key focus of MCT and refer to a type of higher-order beliefs 
that can be defined as ‘beliefs about thinking’. According to MCT, metacognitions act as 
“general plans for processing and coping” (Wells, 2002, p. 18) that govern cognitive 
processes: they influence the choice of maladaptive coping strategies for the management of 
unpleasant cognitions, emotions, and physical feelings. These coping strategies typically 
include rumination, symptom focus (an attentional strategy), and worry. Several types of 
metacognitions have been found to be important in LTHCs (Brown & Fernie, 2015; Cook, 
Salmon, Dunn, & Fisher, 2014; Cook et al., 2015, 2015; Fernie, Maher-Edwards, Murphy, 
Nikcevic, & Spada, 2015; Fernie, Murphy, Wells, Nikcevic, & Spada, 2016; Fernie, Spada, 
& Brown, in press; Fernie, Spada, Ray Chaudhuri, Klingelhoefer, & Brown, 2015; Fisher et 
al., 2018; Fisher, McNicol, Young, Smith, & Salmon, 2015; Fisher, Reilly, & Noble, 2018; 
Kollmann, Gollwitzer, Spada, & Fernie, 2016; Maher-Edwards, Fernie, Murphy, Nikcevic, & 
Spada, 2012; Maher-Edwards, Fernie, Murphy, Wells, & Spada, 2011; Purewal & Fisher, 
2018). For example, positive metacognitive beliefs about the usefulness of a particular coping 
strategy (e.g., “Monitoring my symptoms enables me to better control them”) and negative 
metacognitions that refer to beliefs concerning uncontrollability and danger of a particular 
strategy (e.g., “When I experience symptoms, it’s impossible to focus on anything else”). 
MCT seeks to modify unhelpful metacognitions, disrupting perseverative maladaptive coping 
strategies. 
MCT focuses on cognitive (such as rumination and worry) and attentional processes 
(and their perseveration). Arguably, the role of these processes in distress is shared across 
cultures. For example, just as sustained high blood pressure is not healthy for humans 
regardless of their cultural background, ‘thinking too much’ causes distress to everyone 
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(Kaiser et al., 2015). Although ‘thinking too much’ does not map on to a discrete Western 
psychiatric diagnosis (Kaiser et al., 2015), it seems to be an idiom for distress across the 
world (including Africa, Australia, Central America/Caribbean, the Middle East, South 
America, South Asia, Southeast Asia, and the United States/Europe). ‘Thinking too much’ 
seems to describe a perseverative cognitive process, which is a key component of clinical 
formulations using MCT. It is possible, therefore, that metacognitions may be transcultural 
targets for treatment development. 
1.4 Existing metacognitive measures 
 The Metacognitions Questionnaire 30 (MCQ; Wells & Cartwright-Hatton, 2004) is 
the most often used measure of metacognitions in psychological research. Its items focus on 
positive and negative beliefs about worry, need to control thoughts, cognitive self-
consciousness, and cognitive confidence. More recently, the Metacognitions about Symptom 
Control Scale (MaSCS; Fernie et al., 2015) has been developed to measure beliefs about 
symptom focus, rumination, and worry, first in CFS and later in other LTHCs (Fernie et al., 
in press; Fernie et al., 2015; Kollmann et al., 2016). The key difference between the MaSCS 
and the MCQ lies in the nature and specificity of the metacognitions they are designed to 
measure. The MCQ’s items reflect how it was originally developed (i.e., they mainly describe 
worry-related metacognitions prevalent in people living with Generalized Anxiety Disorder). 
The MaSCS contains items that also refer cognitive and attentional processes, although they 
focus on symptoms (specifically their role in the appraisal, management and control of 
physical symptoms). For example, whereas the MCQ has the item “My worrying thoughts 
persist, no matter how I try to stop them”, the MaSCS has the item “I am not able to stop 
thinking about my symptoms once I start”. Both refer to beliefs about the uncontrollability of 
a cognitive process but, whereas the MCQ item refers to worry in general, the MaSCS item 
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specifically refers to thinking about symptoms. The greater specificity of the MaSCS should 
increase its face validity (compared to the MCQ) in LTHCs. 
However, after using the MaSCS in clinical and research settings for a number of 
years, the current authors have identified weaknesses in some of its items. The seeds of 
concerns about the MaSCS were sowed by clinical and research experience and nurtured by 
theoretical reflection. For example, some participants/patients have reported that four of the 
MaSCS items were difficult to understand (particularly those negatively framed). Regarding 
theoretical concerns, some items (four) refer to metacognitions that describe anticipated 
emotional consequences of engaging in cognitive and/or attentional processes (e.g., the item 
“Thinking about my symptoms makes me feel frustrated” refers to an emotional consequence 
about symptom rumination). These metacognitions do not unpick the relationship between 
cognitive and/or attentional processes with distress, limiting their utility for developing 
theoretical models of distress in LTHCs. Additionally, one MaSCS item does not clearly refer 
to an ongoing cognitive and/or attentional strategy, and instead appears to indicate a 
momentary response to a trigger (“If I focus on the symptom, I can take the appropriate 
action to get better”). This also obfuscates attempts to model the role of metacognitions (and 
their relationships with perseverative cognitive and attentional processes) in LTHC-related 
distress. 
1.5 Study aims 
This study is in two parts and its overall objective is to create three versions of a 
revised MaSCS (i.e., English, German, and Arabic language versions of the MaSCS-R), 
which address the weaknesses of the original MaSCS. Part 1 presents the development of a 
revised (English language) version of the MaSCS-R and used data from a sample of people 
living with CFS (Sample A) from an earlier study (Fernie et al., 2015). Part 2 details the 
creation of German and Arabic versions of the MaSCS-R. As well as using Sample A data, 
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analyses in Part 2 also used data from two different samples (B and C). Data from Sample B 
consisted of a German-speaking people living with FM, also from an earlier study (Kollmann 
et al., 2016). Sample C gathered new data from an Arabic-speaking people living with 
T1DM. The Arabic-speaking sample was recruited out of convenience (i.e., the second author 
is a native Arabic speaker and was able to access this population). The current study also 
aimed to generate evidence for the transcultural validity of the concept of metacognitions 
about symptom control. 
Part 1: Developing an English version of the MaSCS-R 
2. Methods 
2.1 Participants 
Sample A comprised of data from 124 participants, all with a formal diagnosis of CFS 
according to the Oxford Criteria (Sharpe et al., 1991). This data was originally obtained for 
an earlier study, which has been published and provides a detailed description of the 
participants (see Fernie et al., 2015). Table 1 shows basic participant characteristics. 
2.2 Measures and procedure 
The MaSCS-R was created by removing problematic items from the (17-item) 
MaSCS, resulting in eight items. The rationales for removing items are shown in Table 2. 
The MaSCS-R retains the same response format as the MaSCS, using a four-point Likert-
type response format (i.e., “Do not agree”, “Agree Slightly”, “Agree moderately”, and 
“Agree strongly”). Higher scores indicate stronger endorsement of metacognitions. The 
procedure used for collecting data for Sample A is detailed in Fernie et al. (2015). Ethics 
approval was obtained from the local research ethics committee and paper copies of 
questionnaire booklets were sent to participants through the post. 
2.3 Data analysis 
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A principal component analysis was conducted on the proposed eight items of the 
MaSCS-R. Indicators of the latent variables were assessed using a Promax rotation with a 
Kappa of four. A Promax rotation was used because different types of metacognitions 
(e.g., positive and negative) have been found to be associated with each other (Caselli et al., 
2018). This oblique rotation allows assessment of the correlation between factors. Item 
selection was based on the following criteria: (1) if an item loaded less than .4 on a factor it 
was discarded, (2) if an item loaded more than .4 on more than one factor it was discarded, 
and (3) if an item loaded 0.4 or greater on a factor but it’s loading on another factor was 
within .2 it was discarded. This is the same criteria used to develop the original MaSCS 
(Fernie et al., 2015). 
3. Results 
3.1 Principal components analysis 
Scree tests for the MaSCS-R suggested a two-factor solution with Eigen values of 
3.15 and 1.80. The two factors combined accounted for 61.85% of the variance (factor 
loadings are shown in Table 3). Factor 1 is labelled 'positive metacognitions about somatic 
hypervigilance' (P-MASH) and factor 2 'negative metacognitions about the uncontrollability 
and physical repercussions of cognitive and attentional processes' (N-MUR). This factor 
labelling is more specific than the original MaSCS, which also identified two factors but 
named them positive and negative metacognitions about symptom control (Fernie et al., 
2015). Both the P-MASH and the N-MUR factors consisted of four items. 
Part 2: Translations of the MaSCS-R 
4. Methods 
4.1 Participants 
Part 1 briefly outlines participant details for Sample A. Sample B consisted of 348 
participants who reported receiving their FM diagnosis by a physician. The data was 
RUNNING HEAD: Are metacognitions in long-term health conditions transcultural? 
 
11 
originally used in an earlier published study, which provides further participant details (see 
Kollmann et al., 2016). Sample C recruited new participants for the current study. The 
Chronic Care Centre in Lebanon and six clinics of endocrinologists (also in Lebanon) were 
recruitment sources. 91 people with a clinical diagnosis of T1DM took part in the current 
study. Eligible criteria required participants: (1) were Lebanese, (2) were at least 16 years 
old, (3) could read and write in Arabic, and (4) could provide informed consent to participate 
in the study. Parental consent was attained for participants aged 16 or 17 to respect Lebanese 
culture norms. 
4.2 Measures 
4.2.1 Symptom severity 
The Chalder Fatigue Questionnaire (CFQ; Chalder et al., 1993) consists of 14 items 
assessing mental (eight items; e.g., “Do you need to rest more?”) and physical (six items; 
e.g., “Do you have problems with tiredness?”) fatigue over the previous month. The CFQ 
uses four-point Likert-type response format and the current study scores each as either 1, 2, 3, 
or 4, summing them to create a total fatigue score. Higher totals indicate greater fatigue 
severity. The CFQ possesses good psychometric properties with Cronbach’s Alphas of 0.9 
(physical) and 0.8 (mental), as well as a sensitivity of 75.5 and specificity of 74.5 based on a 
ROC cut-off of ¾ (Chalder et al., 1993). Only Sample A provided CFQ data. 
The Fibromyalgia Impact Questionnaire (FIQ; Burckhardt, Clark, & Bennett, 1991) is 
a self-report instrument that assesses the impact of FM on an individual’s life. An algorithm 
was used to generate a total score, with higher scores indicating a greater impact of FM 
symptoms and symptom severity. The current study used data from the German version of 
the FIQ, which possesses acceptable psychometric properties with an internal consistency of α 
= .9, test-retest reliability of .85 and convergence validities with pain and physical 
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functioning scales of between .37 and .65 (Offenbaecher, Waltz, & Schoeps, 2000). Only 
Sample B were administered the FIQ. 
Two measures were used to identify symptom severity in Sample C (consisting of 
people living with T1DM). Firstly, latest glycosylated haemoglobin (HbA1c) test results were 
used to indicate glycaemic control for the past 6 to 8 weeks. In the UK, HbA1c target levels 
are 6.5% for adults living with T1DM (National Institute of Clinical Excellence, 2015). 
Higher levels indicate poorer control of T1DM. Secondly, the 20-item Problem Areas in 
Diabetes (PAID) questionnaire (Polonsky et al., 1995), which uses a five-point Likert-type 
response format, was administered. The current study used the Arabic version of the PAID, 
which has an internal consistency of α = .9 (Alragum, 2008), however its validity has not 
been clearly established. Higher scores reflect greater difficulty living with T1DM. 
4.2.2 Anxiety and depression 
The Depression Anxiety Stress Scale 21 (DASS; Lovibond & Lovibond, 1995) is a 
21-item self-report measure designed to assess depression, anxiety, and stress and was 
administered to Sample A and B. The current study utilized the anxiety and depression 
subscales of the English and German versions of the DASS, with internal consistencies for 
the anxiety and depression subscales for the English version (Henry & Crawford, 2005) of α 
= .8 and α = .9 (respectively) and, respectively, for the German version of α = .8 and α = .9 
(Nilges & Essau, 2015). Sample C were given the Arabic version of the 14-item Hospital 
Anxiety and Depression Scale (HADS) to measure anxiety and depression, which has internal 
consistencies of  α = .7 and α = .8 respectively (Al Aseri et al., 2015; Zigmond & Snaith, 
1983). The HADS has a four-point Likert-type response format. Seven items measure anxiety 
and seven depression symptoms. The HADS has been used with people with T1DM (Santos, 
Bernardo, Gabbay, Dib, & Sigulem, 2013; Strandberg, Graue, Wentzel-Larsen, Peyrot, & 
Rokne, 2014). 




The Metacognitions Questionnaire 30 (MCQ; Wells & Cartwright-Hatton, 2004) is a 
30-item self-report measure that assesses five factors pertaining to metacognition: (1) positive 
beliefs about worry (PW; e.g., “Worrying helps me cope”); (2) negative beliefs about 
thoughts concerning uncontrollability and danger (UNC; e.g., “When I start worrying I 
cannot stop”); (3) cognitive confidence (CC; e.g., “My memory can mislead me at times”); 
(4) beliefs about the need to control thoughts (NCT; e.g., “Not being able to control my 
thoughts is a sign of weakness”); and (5) cognitive self-consciousness (CSC; e.g., “I pay 
close attention to the way my mind works”). Respondents are required to indicate the extent 
of their agreement with the metacognitions using a four-point Likert-type response format. 
Higher scores indicate higher levels of unhelpful metacognitions. The English version of the 
MCQ was used with Sample A, the German version with Sample B  (Möbius & Hoyer, 
2003), and the Arabic version with Sample C (Seleem & Saada, 2015). All three versions of 
the MCQ have been shown to possess acceptable psychometric properties (Möbius & Hoyer, 
2003; Seleem & Saada, 2015; Wells & Cartwright-Hatton, 2004). Note that Sample A’s 
MCQ data has not been reported in earlier published studies. The development of the 
MaSCS-R is described in Part 1. 
The MaSCS and the MCQ have been used in several studies, all reporting that 
metacognitions play a role in distress and/or symptom severity in a wide range of LTHCs. 
For example, metacognitions (as measured by the MCQ) are associated with distress in 
cancer (e.g., Fisher et al., 2018), epilepsy (Fisher et al., 2018), multiple sclerosis (Heffer-
Rahn & Fisher, 2018), HIV (Strodl, Stewart, Mullens, & Deb, 2015), Parkinson’s disease 
(Allott, Wells, Morrison, & Walker, 2005; Brown & Fernie, 2015), and T1DM (Purewal & 
Fisher, 2018). MaSCS factors have been shown to be associated with symptom severity in 
CFS (Fernie et al., 2015; Maher-Edwards et al., 2011) and functional impairment in FM 
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(Kollmann et al., 2016), as well as (tentatively) with distress in Parkinson’s disease (Fernie et 
al., 2015). 
4.3 Translations of the MaSCS-R 
German and Arabic versions of the MaSCS-R were created using the backward-
forward translation approach and tried to adhere to guidelines described by the International 
Test Commission (2017). The forward translations (English to German and Arabic) were 
carried out by two independent professional translators, both native speakers of German or 
Arabic and proficient in English. The research teams reviewed the two translations and 
agreed on a combined version. Two other independent translators, both native speakers of 
English, fluent in German or Arabic, and blind to the original English version, back-
translated the combined version into English. These English translations were compared with 
the original English MaSCS/MaSCS-R items to check that their meanings were congruent. 
4.4 Procedure 
The procedure used to gather data from Sample A is described in Part 1. Experimental 
procedures for gathering data from Sample B is described in an earlier published study (see 
Kollmann et al., 2016). The research with Sample B was conducted in accordance with the 
declaration of Helsinki. The questionnaires administered to Sample B were administered 
online. Potential participants for Sample C were informed about the study during routine 
clinical appointments. Sample C participants were given paper versions of the questionnaires. 
4.5 Data analysis. 
4.5.1 Translations and psychometric, transcultural, and transdiagnostic properties of the 
MaSCS-R 
German and Arabic versions of the MaSCS-R were created using the back-forward 
translation process to enhance conceptual equivalency (Beaton, Bombardier, Guillemin, & 
Ferraz, 2000). Confirmatory factor analyses (CFA), using the Lavaan package (Rosseel, 
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2012), were conducted on the datasets to test model fit of the two-factor structure of the 
MaSCS-R across all three versions. The data obtained from the eight items of the MaSCS-R 
for all datasets were assessed (separately) to identify deviations from univariate and 
multivariate normal distribution. The result of these analyses determined the method of 
estimation used in the CFAs or whether to approach the analysis with Item Response Theory 
(CFA is better able to deal with non-normal factors). The Root Mean Square Error of 
Approximation (RMSEA), the Standardized Root Mean Residual (SRMR), Comparative Fit 
Index (CFI), and the Chi-square test were employed to evaluate model fit and measurement 
invariance. Thresholds to indicate acceptable model fit used were: RMSEA <= .08, SRMR 
<= .08, CFI >= .95, and nonsignificant Chi-square values (Browne, Cudeck, Bollen, & Long, 
1993; Schermelleh-Engel, Moosbrugger, & Müller, 2003). Measurement invariance was 
examined using the procedure described by Xu and Tracey (2017), which involves three 
progressive steps that assess configural, metric, and scalar invariance. If configural variance 
is supported, then it would suggest that the latent constructs are indicated by the observations 
(i.e., the responses to MaSCS-R items) across samples. For this study, configural invariance 
would suggest that the latent constructs P-MASH and N-MUR are measured by a stable 
pattern of MaSCS-R items across English-speaking people living with CFS, German-
speaking people living with FM, and Arabic-speaking people living with T1DM (providing 
initial evidence to suggest that the N-MaSCS-R and metacognitions have transcultural and 
transdiagnostic validity). Support for metric invariance would suggest that the psychological 
meanings of P-MASH and N-MUR hold across samples (providing further evidence that the 
MaSCS-R and metacognitions possess transcultural and transdiagnostic validity). While 
support for scalar invariance would suggest that equivalent mean scores are found across 
samples. Findings indicating scalar variance might be a result of transdiagnostic and/or 
transcultural differences. 
RUNNING HEAD: Are metacognitions in long-term health conditions transcultural? 
 
16 
4.5.2 Concurrent validity 
The following analyses were computed using version 24 of SPSS (International 
Business Machines Corporation, 2017). The distributions of P-MASH, N-MUR, all the five 
MCQ factors, CFQ, FIQ, HbA1c, and PAID scores were examined for each sample 
separately. Anxiety and depression scores (measured by the DASS and HADS) were 
converted into z-scores for each sample separately. This created standardised anxiety (stA) 
and depression (stD) scores but did not alter their distributions in each sample’s dataset (i.e., 
nonnormally distributed variables do not become normal). These two new variables were 
used to provide standardized anxiety and depression scores across samples despite the 
different measures used (this was needed for the later multiple imputation). The patterns of 
missing values for the variables shared across samples (i.e., P-MASH, N-MUR, all the five 
MCQ factors, stA, and stD) were examined and five iterations of multiple imputation were 
used to predict missing data. To examine concurrent validity for each version of the MaSCS-
R, the dataset from the final iteration of the multiple imputation was used to compute 
correlation analyses between study variables. 
5. Results 
5.1 Participant characteristics 
Table 1 shows basic demographic details for all three samples. For measures of 
symptom severity, Sample A had a mean CFQ score of 41.6 (SD = 10.1; range 14 to 56) and 
Sample B had a mean FIQ score of 67.1 (SD = 14.6; range 6.2 to 96.9). Sample C’s mean 
HbA1c was 8.2% (SD = 1.5; range 5.9 to 14.0) and mean PAID score was 28.6 (SD = 18.8; 
range 0 to 69). 
5.2 Factor structure, measurement invariance and internal consistencies 
The data from each three groups were found to be multivariate non-normal. 
Accordingly, all CFAs were estimated with Diagonal Weighted Least Squares. The two-
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factor structure of the MaSCS-R developed in Part 1, and its German and Arabic versions 
(see Supplemental material 1), were a good fit of the data obtained from all three samples 
(see Table 4 – note that this table reports an n of 79 rather than 91 because the analyses used  
complete datasets). This also indicate that the MaSCS-R possesses configural invariance: i.e., 
MaSCS-R items measure the latent factors stably across all three samples. To examine metric 
invariance, data from all three samples was combined to contribute to the analysis. First, a 
model that allowed for loadings to be freely estimated was built and tested (Model A). This 
was compared to a second model that constrained loadings to be equal across all groups 
(Model B). Both of these models fits were good fits of the data (Table 4). A Chi-square test 
revealed a nonsignificant difference in model fit between Model A and Model B (Chi-square 
= 17.963, df = 12, p = .1168), and the difference in CFIs between models was less than .01. 
This suggests that the psychological meaning of the metacognitive constructs (represented by 
the latent factors) were invariant across the three samples. The configural and metric 
invariance found in the MaSCS-R data provides evidence that the measure possesses 
transcultural and transdiagnostic validity. The data for MaSCS-R was not scalar invariant: 
i.e., the different samples scored on average different levels for the latent variables (Chi-
squared = 121.186, df = 4, p < .001). The English, German, and Arabic language versions of 
the MaSCS-R had mostly acceptable and good internal consistencies for both factors 
(Cronbach’s alpha = 0.7 to 0.8), apart from the N-MUR factor from the Arabic version of the 
MaSCS-R, which was questionable (Cronbach’s alpha = 0.6). Note that Cronbach’ alphas of 
0.6 < 0.7 are considered questionable, 0.7 <0.8 acceptable and 0.8 < 0.9 good (DeVellis, 
2016). Table 4 also shows the means. SDs and ranges of P-MASH and N-MUR for each 
sample. 
5.3 Concurrent validity 
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Kolmogorov-Smirnov tests indicated that the distributions of study variables were 
non-normal. Study variables shared across all three samples (i.e., MaSCS-R, MCQ, stA, and 
stD) had missing values that were assessed as MAR or MCAR. Multiple imputation was used 
to predict missing values. Spearman’s rho correlation analyses were conducted on the study 
variables resulting from the fifth iteration of the multiple imputation (Table 5). P-MASH was 
positively associated with anxiety in CFS, whereas N-MUR was significantly related to 
anxiety and depression in all samples. In most samples, all MCQ factors were associated with 
anxiety (except for NCT in T1DM) and depression (the exceptions again were in the T1DM 
sample, i.e., with PW, NCT, and CSC). P-MASH was significantly related to PW in the CFS 
and FM, but not the T1DM, samples. However, P-MASH was associated with metacognitive 
factors (measured by the MCQ) in T1DM (i.e., with CC and CSC), suggesting some 
convergence in the measurement of metacognitive constructs (hinting at concurrent validity). 
The N-MUR was significantly related to nearly all MCQ factors in all samples – the 
exceptions being with PW and CSC in T1DM. All metacognitive factors were associated 
with symptom severity in CFS and FM (bar CSC in CFS and P-MASH in FM). In T1DM, 
only N-MUR, UNC, and NCT were significantly related to HbA1c levels. Similar significant 
associations between metacognitive factors and PAID were found, with the addition of 
relationships with PW and NCT. 
6. Discussion 
This study sought to create revised versions of an existing metacognitive 
questionnaire (the MaSCS-R) in three languages. All versions of the MaSCS-R comprised of 
eight items equally distributed over two factors. The first factor consisted of items that 
described positive metacognitions about symptom hypervigilance (P-MASH), and the second 
negative metacognitions about the uncontrollability and physical repercussions of engaging 
in symptom focus, rumination, and/or worry (N-MUR). The current study provides 
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preliminary evidence that the English, German, and Arabic versions of the two-factor, eight-
item MaSCS-R possesses acceptable psychometric properties. The findings also suggest that 
the psychological meanings behind the construct of metacognitions are shared across three 
countries (and two cultures: i.e., Western and Lebanese Arabic) as evidenced by the findings 
that supported the configural and metric invariance of the MaSCS-R. This provides evidence 
to support the contention that metacognitions, as measured by MCQ, as well as the 
metacognitions about symptom control, as measured by MaSCS-R, have transcultural and 
transdiagnostic validity. 
 The current study’s findings align with those from earlier research that examined the 
relationship between distress in LTHCs and metacognitions. For example, all MCQ factors 
were significantly associated with anxiety and depression in CFS, mirroring the results 
reported by Maher-Edwards et al. (2011). The results presented here also align with those 
reported by Purewal and Fisher (2018), who found that UNC and CC were significantly 
associated with anxiety and depression, in a sample of people living with T1DM in the UK. 
The current study’s findings identified additional relationships between two MCQ factors 
(PW and CSC) and anxiety, and between NCT and both anxiety and depression, in an Arabic-
speaking sample of people living with T1DM. This suggests that metacognitions play a role 
in LTHC-related distress, and that it is possible this role possesses a degree of 
stability transculturally. 
The CFS and FM samples were both drawn from Western countries and have LTHCs, 
where the aetiologies of their conditions are not currently understood, nor can they be 
diagnosed with a specific test (Rollnik, 2017; Wolfe & Häuser, 2011). Unlike the T1DM 
sample, which was drawn from a non-Western country (i.e., Lebanon, with a ‘Middle-
Eastern/Lebanese Arabic’ culture) with LTHC that can be diagnosed with a series of specific 
tests. Western and Arabic samples showed a similar pattern of relationships with anxiety and 
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MCQ metacognitions, except NCT was significant in samples A and B but not C. This 
pattern was nearly identical for depression relationships, with addition of PW being 
significant in samples A and B but not C. MCQ metacognitions showed similar pattern of 
significance across all three samples with measures of symptom severity, apart from HbA1c 
levels whose only significant relationship was with UNC. However, overall the current 
study’s finding suggests that the MCQ possesses transcultural and transdiagnostic concurrent 
validity. 
 The current study’s offered mixed support for the transcultural and transdiagnostic 
concurrent validity of the MaSCS-R. While N-MUR was significantly associated with 
anxiety, depression, and measures of symptom severity in all samples, P-MASH was related 
to anxiety and symptom severity only in CFS. This suggests that the P-MASH has concurrent 
validity only in CFS, while the N-MUR has transcultural and transdiagnostic concurrent 
validity. However, P-MASH was significantly associated with at least two MCQ factors 
across each sample, suggesting that, to an extent, P-MASH has some transcultural 
and/or transdiagnostic concurrent validity. 
 The current study did not find a significant relationship between P-MASH with either 
anxiety or depression in the FM and T1DM samples, nor with FIQ, HbAc1 or PAID. In terms 
of FM, this finding is similar to that found by Kollmann et al. (2016) who used the original 
MaSCS. In their study, positive metacognitions about symptom control was also not 
significantly related to anxiety, depression and total FIQ scores (but were related to some FIQ 
and MCQ subscales). In terms of T1DM, regular (but not continuous) symptom focus (as 
measured by P-MASH) is an adaptive strategy that helps to monitor blood glucose levels and 
providing alerts to hyper/hypoglycaemia. Such alerts act as stop signals to symptom focus 
that require discrete action (e.g., an injection of insulin). This contrasts with CFS, where 
symptom focus appears not to have a clear stop signal or defined goal other than identifying 
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fatigue: this might be responded to with activity reduction (fear-avoidance) in response, 
which is hypothesised to help maintain fatigue (e.g., Deale, Chalder, & Wessely, 1998). 
Brown and Fernie (2015) suggested that using the full spectrum of CBT interventions 
to treat distress in Parkinson’s disease (also a LTHC) might not be possible. For example, 
some thoughts and beliefs about symptoms may represent accurate appraisals of living with a 
LTHC (e.g., ‘there is no cure for this disease’) and therefore would be inappropriate for 
reality-testing. However, the validity of thoughts and belief about living with the symptoms 
of a LTHC is not relevant to metacognitions. Thus, if metacognitions are later shown to have 
a causal effect on LTHC-related distress, future treatment packages could be designed by 
selecting from the entire ‘menu’ of MCT interventions, including those that involve the 
reality-testing of metacognitions. This prospect is made more attractive considering the 
reported effectiveness of MCT over CBT in treating anxiety and depression (Normann & 
Morina, 2018; Normann, van Emmerik, & Morina, 2014). 
The current study is subject to several limitations. First, study variables were 
vulnerable to response biases (e.g., retrospective and social desirability biases). Second, the 
current study relied on cross-sectional data meaning that causality cannot be determined. 
Third, the current study did not clearly establish the concurrent transcultural and/or 
transdiagnostic concurrent validity of P-MASH. Fourth, missing HbA1c and PAID data in 
Sample C meant that only 69 cases were used in the correlation analyses. Consequently, 
statistical power was impaired, and the analyses may have failed to identify relationships 
between metacognitions and symptom severity in T1DM. Additionally, the validity of the 
Arabic PAID has not been clearly established, and therefore might not measure problem 
areas associated with living with diabetes in this population. Fifth, factors that could affect 
HbA1c levels were not controlled for (e.g., lifestyle changes and new medications). This 
restricts the confidence in interpretations of HbA1c results. Sixth, the transcultural validity of 
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the MaSCS-R requires further testing in other cultures and languages (e.g., Japanese, 
Spanish, etc.). Seventh, the N-MUR factor of the Arabic MaSCS-R had questionable internal 
consistency. This could be the result of the relatively smaller sample size; this explanation 
needs to be tested in future studies. Eighth, the validity of the Arabic PAID has not been 
clearly established, meaning that is uncertain whether it measures problem areas in diabetes 
in the Lebanese sample (C). Finally, the samples used in the current study meant there was 
limited control of transcultural and transdiagnostic factors. As a result, differences in the 
relative contribution of metacognitions to distress across LTHCs and cultures could not be 
clearly established (i.e., does P-MASH have a stronger relationship with distress depending 
on the cultural background of the sample, the sample’s LTHC, or a combination of both?). 
Future studies could use the MaSCS-R with samples living with the same LTHC drawn from 
different cultural populations and samples drawn from a specific population living with 
different LTHCs. 
 The current study produced three versions of the MaSCS-R and its findings support 
the contention that the construct of metacognitions has transcultural validity. The MaSCS-R 
offers a new method for identifying transcultural targets for psychological intervention that 
seek to ameliorate distress in LTHCs. Further research is required to confirm the 
psychometric properties of the MaSCS-R.
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Table 1: Participant characteristics for all samples 
 
CFS (Sample A) FM (Sample B) T1DM (Sample C) 
N 124 348 91 
Data source PD PD OD 
Females: N (%) 97 (75.8%) 316 (90.8%) 52 (57.1%) 
Mean age (range) in years 41.7 (18 to 70) 49.9 (23 to 74) 30.0 (16 to 39) 
Standardized anxiety range -1.11 to 3.02 -1.86 to 2.43 -1.42 to 3.68 
Standardized depression range -1.21 to 1.98 -1.94 to 2.28) -1.24 to 2.77 
Note. CFS = Chronic Fatigue Syndrome.; FM = Fibromyalgia; T1DM = Type 1 Diabetes Mellitus; PD = Published Data; OD = Original Data; n = 563. 
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Table 2: Rational for item removal to create the MaSCS-R 
Original MaSCS items Rationale 
When I experience symptoms, it’s impossible to focus on anything else N/A: retained for MaSCS-R 
If I focus on the symptom, I can take the appropriate action to get better Belief seems to refer to a nebulous behaviour instigated in response to a trigger. 
Ruminating about my symptoms helps me to figure out how to deal with them Some patients and research participants have difficulty understanding the meaning of ‘rumination’. 
Thinking about my symptoms makes me feel frustrated Refers to an emotional consequence. 
If I don’t pay attention to my symptoms, I could push myself too far Feedback from patients and participants reported that this item was not clear/difficult to understand. 
Monitoring my symptoms helps me to predict how they will develop N/A: retained for MaSCS-R 
Thinking about my symptoms makes me feel negative and down Refers to an emotional consequence. 
I monitor my symptoms, so I can figure out my physical limitations N/A: retained for MaSCS-R 
Thinking about my symptoms makes me feel exhausted N/A: retained for MaSCS-R 
Monitoring my symptoms enables me to better control them N/A: retained for MaSCS-R 
Focusing on my symptoms makes me feel anxious or stressed Refers to an emotional consequence. 
Monitoring my symptoms helps to keep me safe N/A: retained for MaSCS-R 
I am not able to stop thinking about my symptoms once I start N/A: retained for MaSCS-R 
By focusing on my symptoms, I can detect when I am getting better Feedback from patients and participants reported that this item was not clear/difficult to understand. 
Not paying attention to my symptoms could lead to my illness getting worse Feedback from patients and participants reported that this item was not clear/difficult to understand. 
Focusing on my symptoms makes me feel down Refers to an emotional consequence. 
Thinking about my symptoms could make them worse N/A: retained for MaSCS-R 
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Note. MaSCS(-R ) = Metacognitions about Symptom Control Scale (- Revised); Bold text indicates items retained for the MaSCS-R; n = 124. 
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Table 3: Factor loadings for principal components analysis 
MaSCS-R items 1 2 
Monitoring my symptoms enables me to better control them 0.862 -0.029 
Monitoring my symptoms helps me to predict how they will develop 0.827 0.049 
I monitor my symptoms, so I can figure out my physical limitations 0.824 -0.036 
Monitoring my symptoms helps to keep me safe 0.751 0.026 
Thinking about my symptoms makes me feel exhausted -0.133 0.807 
I am not able to stop thinking about my symptoms once I start 0.049 0.800 
Thinking about symptoms could make them worse 0.037 0.712 
When I experience symptoms, it's impossible to focus on anything else 0.066 0.667 
Note. MaSCS-R = Metacognitions about Symptom Control Scale – Revised; n = 124. 
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Table 4: P-MASH and N-MUR descriptive statistics and configural and metric invariance across the three study samples 
  
P-MASH N-MUR 
   
RMSEA 
 
Model n Mean (SD); range Chi-squared df CFI Estimate 95% CI SRMR 
CFS English (Sample A) 124 9.43 (3.17); 4-
16 
8.58 (3.09); 4- 
16 
6.807 19 1.000 0.000 [0, 0] 0.040 




44.250 19 0.963 0.062 [0.038, 0.086] 0.060 




11.327 19 1.000 0.000 [0, 0.039] 0.070 
Model A: all loadings freely estimated 550 
N/A 
62.384 57 0.995 0.023 [0, 0.052] 0.052 
Model B: factor loadings invariant 550 83.499 69 0.988 0.034 [0, 0.057] 0.060 
Note. CFS = Chronic Fatigue Syndrome.; FM = Fibromyalgia; T1DM = Type 1 Diabetes Mellitus; All Chi-square values were non-significant. 
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Table 5: Multi-group Spearman’s rho correlation matrix 
  1 2 3 4 5 6 7 
Variables/Sample A B C A B C A B C A B C A B C A B C A B C 
1. P-MASH 
   
.40** -.02 -.04 .33** .33** -.10 .29** -.04 -.12 .23** .03 -.24* .38** .06 -.05 .30** .18** .24* 
2. N-MUR 
      
.35** .32** -.02 .54** .62** .31** .34** .37** .33** .48** .50** .26* .42** .49** -.08 
3. PW 
         
.54** .38** .29** .27** .26** .05 .79** .47** .04 .46** .50** .03 
4. UNC 
            
.47** .46** .21* .65** .71** .09 .57** .69** -.30** 
5. CC 
               
.41** .48** -.08 .21* .41** -.07 
6. NCT 
                  
.56** .67** .17 
7. CSC 
                     
8. stA .21* -.01 -.18 .37** .57** .31** .49** .37** .21* .54** .72** .55** .52** .49** .30** .62** .58** .14 .33** .56** .21* 
9. stD .12 -.04 -.07 .43** .58** .31** .42** .32** .08 .52** .68** .45** .55** .50** .23* .53** .56** .03 .35** .53** .12 




























































Note. A = Sample A (Chronic Fatigue Syndrome); B  = Sample B (Fibromyalgia); C = Sample C (Type 1 Diabetes Mellitus); P-MASH = positive 
metacognitions about somatic hypervigilance; N-MUR = negative metacognitions about the uncontrollability and physical repercussions of cognitive and 
attentional processes; PW = positive metacognitions about worry; UNC = uncontrollability and danger metacognitions about worry; CC = lack of cognitive 
confidence; NCT = need to control thoughts; CSC = cognitive self-consciousness; stA = standardized anxiety; stD = standardized depression; CFQ = Chalder 
Fatigue Questionnaire; FIQ = Fibromyalgia Impact Questionnaire; HbA1c  = glycosylated haemoglobin levels; PAID = Problem Areas in Diabetes ; * = p < 
.05; ** = p < .01, Sample A:  n = 122 (symptom severity variables) to 144; Sample B: n = 347; Sample C: n =69 (symptom severity variables) to 91. 
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Supplementary materials 1: English, German, and Arabic versions of the MaSCS-R 
English German Arabic Factor 
When I experience symptoms, it’s 
impossible to focus on anything else 
Wenn sich die Symptome bemerkbar machen, kann ich mich 
unmöglich auf irgendetwas anderes konzentrieren 
عندما اواجھ أعراض، یستحیل 
أن أرّكز على أي شيء آخر  
N-MUR 
Monitoring my symptoms helps me to 
predict how they will develop 
Meine Symptome zu beobachten hilft mir dabei, ihre Entwicklung 
vorherzusehen 
مراقبة أعراضي تساعدني على 
توقع كیف ستطور   
P-MASH 
I monitor my symptoms, so I can figure out 
my physical limitations 
Ich beobachte meine Symptome genau, damit ich meine 
körperlichen Grenzen erkenne 
أراقب أعراضي لأكتشف  
حدودي الجسدیّة  
P-MASH 
Thinking about my symptoms makes me 
feel exhausted 
Über meine Symptome nachzudenken erschöpft mich التفكیر في أعراضي یشعرني 
بالإرھاق  
N-MUR 
Monitoring my symptoms enables me to 
better control them 
Auf meine Symptome zu achten hilft mir, sie besser in den Griff zu 
bekommen 
مراقبة أعراضي تسمح لي 
السیطرة علیھا بشكل أفضل  
P-MASH 
Monitoring my symptoms helps to keep me 
safe 
Auf meine Symptome zu achten gibt mir Sicherheit مراقبة أعراضي تساعدني على 
البقاء سلیًما  
P-MASH 
I am not able to stop thinking about my 
symptoms once I start 
Wenn ich einmal damit anfange, über meine Symptome 
nachzudenken, kann ich nicht mehr aufhören 
عندما أبدأ في التفكیر بأعراضي، 
لا أستطیع التوقف.  
N-MUR 
Thinking about my symptoms could make 
them worse 














English German Arabic Score 
Do not agree Trifft nicht zu لا توافق  1 
Agree slightly trifft eher zu توافق قلیلا  2 
Agree moderately trifft zu توافق باعتدال  3 
Agree very much trifft stark zu توافق كثیرا  4 
 
 
 
